ATORVALIQ
- Product NDC
- 46287-030
- 11-digit product format
- 462870030
- Labeler code
- 46287
- Product ID
- 46287-030_fb92775a-6d6d-4d62-ab23-045f16ec5895
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- ATORVALIQ
- Dosage form
- SUSPENSION
- Route
- ORAL
- Labeler
- CMP Pharma, Inc.
- Application
- NDA213260
- Marketing category
- NDA
- Marketing start
- 2023-03-01
- Substance
- ATORVASTATIN CALCIUM TRIHYDRATE
- Active strength
- 20 mg/5mL
- Pharmacologic classes
- HMG-CoA Reductase Inhibitor [EPC], Hydroxymethylglutaryl-CoA Reductase Inhibitors [MoA]
- NDC exclude flag
- No
- Listing certified through
- 2026-12-31
- Current FDA listing
- Yes
Additional Listing Data#
- Finished product
- Yes
- Brand name base
- ATORVALIQ
- Listing expiration
- 2026-12-31
Active Ingredients#
Ingredient, Strength table| Ingredient | Strength |
|---|
| ATORVASTATIN CALCIUM TRIHYDRATE | 20 mg/5mL |
Harmonized Identifiers#
Field, Values table| Field | Values |
|---|
| Unii | 48A5M73Z4Q |
| Rxcui | 2630760 |
DailyMed Product Concepts#
DailyMed Package Descriptions#
Package NDC, Product, Description table| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|
| 46287-030-01 | ATORVALIQ | 150 mL in 1 BOTTLE | Suspension | 150 | | 3 |
DailyMed Dashboard NDC Coverage#
NDC, Dashboard title, SPL version table| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|
| 46287-030 | ATORVALIQ SUSPENSION [CMP PHARMA, INC.] | 3 | Current NDC, 1 package rows | 20240823_41fca2d8-7f3f-45b9-8974-81b89accc211.zip |
DailyMed RxNorm Mappings#
Packages#
Package NDC, 11-digit format, Description table| Package NDC | 11-digit format | Description | Units | Marketing start | Sample | Exclude flag | Status |
|---|
| 46287-030-01 | 46287003001 | 150 mL in 1 BOTTLE (46287-030-01) | 150 ml | 2023-03-01 | No | No | Historical |